

1 **Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac**
2 **(CoronaVac) followed by AstraZeneca (Vaxzevria)**

3

4 Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakkhana Wongsrisang,
5 Natthinee Sudhinaraset, Sompong Vongpunsawad, Yong Poovorawan

6

7 Chulalongkorn University, Bangkok, Thailand (R. Yorsaeng, P. Vichaiwattana, S. Klinfueng,
8 L. Wongsrisang, N. Sudhinaraset, S. Vongpunsawad, Y. Poovorawan)

9

10 **Address for correspondence:** Sompong Vongpunsawad, Center of Excellence in Clinical
11 Virology, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan,
12 Bangkok 10330, Thailand; email: sompong.vo@chula.ac.th; phone: +66 2 256 4909; fax: +66
13 2 256 4929.

14

15 **Running Title:** Heterologous prime-boost with CoronaVac-AZD1222

16 **Keywords:** vaccine, coronavirus, Sinovac, AstraZeneca, COVID-19

17 **Abstract**

18 Limited COVID-19 vaccines in many countries have delayed mass-immunization. Although
19 individuals fully vaccinated with Vaxzevria (AstraZeneca) have higher antibody levels than
20 those with CoronaVac (Sinovac), heterologous prime-boost with CoronaVac-Vaxzevria
21 yielded comparable antibody levels to two-dose Vaxzevria. Combination use of different
22 available vaccines may be warranted in Thailand, which faces limited vaccine choice and
23 supply.

24 The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
25 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has outstripped vaccine
26 availability and timely delivery from vaccine companies (1). Less affluent countries,
27 including Thailand, have limited access to vaccines and must rely on whatever vaccines are
28 available on the world market. Due to difficulties in securing sufficient stock for mass
29 immunization, Thai Food and Drug Administration initially approved for emergency use two
30 COVID-19 vaccines beginning in 2021. CoronaVac from Sinovac, for use in individuals 18-
31 59 years of age, is an inactivated SARS-CoV-2 produced from Vero cells. Recent study in
32 Chile involving >10 million people who received two-dose CoronaVac reported the adjusted
33 vaccine effectiveness of 65.9% in preventing COVID-19 (2). In contrast, Vaxzevria
34 (previously AZD1222) from AstraZeneca (approved for use in individuals 18 or older)
35 utilizes an adenoviral vector expressing SARS-CoV-2 spike (S) protein, which has proven to
36 elicit robust immune response in phase II/III trial (3).

37 CoronaVac arrived into Thailand from February to June 2021, while a batch of
38 Vaxzevria arrived in February. Additional Vaxzevria only became available in June from a
39 domestic vaccine production facility. Based on available scientific evidence at the time and
40 given the uncertainties of vaccine procurement and delivery, the Thai Advisory Committee
41 on Immunization Practice endorsed a vaccination guideline of the two-dose CoronaVac (2-4
42 weeks apart) and Vaxzevria (10-12 weeks apart) (4). Since then, limited vaccine availability
43 due to delivery delays has occasionally resulted in heterologous vaccination. Moreover,
44 vaccine-related complications in individuals who had initially received CoronaVac were
45 reported (body rash, anaphylaxis, and immunization stress-related response requiring
46 hospitalized care). Due to the need to attain two-dose regimen, some vaccinees received
47 Vaxzevria as second dose.

48 While conducting a serological study among individuals fully vaccinated with either
49 two-dose CoronaVac (3 weeks apart) or two-dose Vaxzevria (~10 weeks apart) compared to
50 COVID-19 convalescent patients (4-6 weeks post-symptom onset) (5), we had the
51 opportunity to evaluate immune response among vaccinees who had received CoronaVac
52 followed by Vaxzevria (~4 weeks apart) at King Chulalongkorn Memorial Hospital in
53 Bangkok. The study was approved by the Institutional Review Board of Chulalongkorn
54 University (IRB number 192/64). Sera from individuals who received two-dose CoronaVac
55 (n=80, mean age 42 years), CoronaVac-Vaxzevria (n=54, mean age 38 years), and two-dose
56 Vaxzevria (n=80, mean age 48 years) were evaluated for SARS-CoV-2 anti-S antibodies
57 post-vaccination (Table) by using the Elecsys anti-SARS-CoV-2 S on the cobas e 411
58 analyzer according to the manufacturer's instructions (Roche Diagnostics, Mannheim
59 Germany). This qualitative electrochemiluminescence immunoassay measures total
60 antibodies to the S protein receptor binding domain (values ≥ 0.8 U/mL cutoff was considered
61 reactive).

62 We observed that the geometric mean antibody titer among the two-dose CoronaVac
63 vaccinees was 96.4 U/mL (95% CI: 76.1-122.1), which was not significantly more than the
64 mean of 78 U/mL (95% CI: 52.8-115.8) observed among convalescent individuals ($p=0.68$)
65 (Figure). In comparison, the mean antibody level among the CoronaVac-Vaxzevria vaccinees
66 (797 U/mL; 95% CI: 598.7-1062) was comparable to that of vaccinees who received two-
67 dose Vaxzevria (818 U/mL; 95% CI: 662.5-1010), which was not a significant difference
68 ($p=0.49$). These results suggest that the heterologous prime-boost with CoronaVac followed
69 by Vaxzevria may provide better antibody response than two doses of CoronaVac and induce
70 similar levels of antibody induction as elicited by two doses of Vaxzevria.

71 A limitation in this study is that the immunoassay quantified all immunoglobulins in
72 the serum samples and did not distinguish between the short-term immunity conveyed by

73 IgM and the longer-lasting IgG. In this regard, such measurement of seroconversion may or
74 may not be associated with protection. We were also unable to ascertain virus-specific
75 neutralizing antibodies nor quantify specific T-cell response. In retrospect, it would have
76 been ideal to solicit adverse events associated with heterologous vaccination from individuals
77 at the time of sample collection. Finally, the Roche assay used in this study may not have
78 accurately reflected the antibody measurement specific to the current SARS-CoV2 variants in
79 circulation.

80 The desire to maximize antibody response elicited from different SARS-CoV-2 vaccine
81 platforms with vaccine cost and availability under extenuating circumstances warrants
82 examination of heterologous prime-boost regimen (6). Such schedule is unconventional under
83 normal circumstances and efficacy data are urgently needed. However, recent preliminary
84 studies from Spain, Germany, and United Kingdom describing heterologous vaccination
85 using vaccines from Pfizer and AstraZeneca suggest that this combination was generally safe
86 and effective (7-10). Heterologous vaccine use may be especially warranted in Thailand and
87 other developing nations where constraints in delayed vaccine supply and availability are
88 exceptional. Considering the fact that inactivated vaccines are readily procured while viral
89 vectored vaccines await production and delivery, the Thai government implemented
90 CoronaVac-Vaxzevria regimen beginning on July 12, 2021. Similar strategies are under
91 consideration in other Southeast Asian nations including Vietnam and the Philippines, which
92 are also facing vaccine shortages and uncertainties in immune protection afforded by
93 CoronaVac. In summary, serological values reported here provide evidence-based
94 justification for further evaluation of heterologous vaccine use, especially the combination of
95 inactivated and S-encoding vaccine prime-boost schedule.

96 **References**

- 97 1. Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for
98 COVID-19: Where do we stand in 2021? *Paediatr Respir Rev*. In press 2021.
- 99 2. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.
100 Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med*.
101 2021;NEJMoa2107715. doi: 10.1056/NEJMoa2107715. Epub ahead of print.
- 102 3. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et
103 al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1
104 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults
105 (COV002): A single-blind, randomised, controlled, phase 2/3 trial. *Lancet*.
106 2021;396:1979-93. doi: 10.1016/S0140-6736(20)32466-1.
- 107 4. Department of Disease Control. COVID-19 vaccination guideline under pandemic
108 B.E.2564, Thailand. Department of Disease Control, Ministry of Public Health. Feb
109 2021:12. <https://www.ddc.moph.go.th/uploads/files/1729520210301021023.pdf>
- 110 5. Chirathaworn C, Sripramote M, Chalongviriyalert P, Jirajariyavej S, Kiatpanabhikul
111 P, Saiyarin J, et al. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and
112 the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and
113 close contacts, Thailand, April-June 2020. *PLoS One*. 2020;15:e0236905. doi:
114 10.1371/journal.pone.0236905
- 115 6. Dyani L. Mix-and-match COVID vaccines: the case is growing, but questions remain.
116 *Nature*. 2021;595:344-5. <https://doi.org/10.1038/d41586-021-01805-2>
- 117 7. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD; Com-
118 COV Study Group. Heterologous prime-boost COVID-19 vaccination: Initial
119 reactogenicity data. *Lancet*. 2021;397:2043-6. doi: 10.1016/S0140-6736(21)01115-6

- 120 8. Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S, et al. Safety,
121 reactogenicity, and immunogenicity of homologous and heterologous prime-boost
122 immunisation with ChAdOx1-nCoV19 and BNT162b2: A prospective cohort study.
123 medRxiv [Preprint]. 2021 [cited 2021 Aug 5]. Available from:
124 <https://doi.org/10.1101/2021.05.19.21257334>
- 125 9. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity
126 and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared
127 with homologous vaccine regimens. medRxiv [Preprint]. 2021 [cited 2021 Aug 5].
128 Available from: <https://doi.org/10.1101/2021.06.13.21258859>
- 129 10. Borobia AM, Carcas AJ, Perez-Olmeda MT, Castano L, Bertran MJ, Garcia-Perez J,
130 et al. Reactogenicity and immunogenicity of BNT162b2 in subjects having received a
131 first dose of ChAdOx1s: Initial results of a randomised, adaptive, phase 2 trial
132 (CombiVacS). SSRN [Preprint]. 2021 [cited 2021 Aug 5]. Available from:
133 <https://doi.org/10.2139/ssrn.3854768>

134 **Acknowledgements**

135 This work was supported by The National Research Council of Thailand (NRCT), Health
136 Systems Research Institute, The Center of Excellence in Clinical Virology of Chulalongkorn
137 University, and King Chulalongkorn Memorial Hospital.

138

139 **Conflict of Interest**

140 The authors declare no conflict of interest. None of the authors have any financial interests
141 with Sinovac nor AstraZeneca.

142 **Legend**

143 **Figure. Serum immunoglobulins against SARS-CoV-2 spike in the fully vaccinated,**
144 **heterologous prime-boost, and convalescent patients.** Antibodies were evaluated by using
145 the Elecsys anti-SARS-CoV-2 S receptor binding domain on the Roche cobas e411 analyzer.
146 Long horizontal bars denote the geometric mean titer (GMT). Short horizontal bars denote
147 upper and lower 95% confidence intervals (CI). Asterisk denotes statistical significance
148 ($P < 0.0001$); ns = not significant. AZD1222 is now Vaxzevria.

149 **Table. Parameters of serological samples in this study**

| | CoronaVac-CoronaVac | CoronaVac-Vaxzevria | Vaxzevria-Vaxzevria | Convalescent |
|--------------------------------------------|----------------------------|----------------------------|----------------------------|---------------------|
| Individuals | n=80 | n=54 | n=80 | n=91 |
| Age (years) | | | | |
| range | 18-59 | 21-52 | 20-78 | 2-64 |
| mean | 42.0 | 38.3 | 48.1 | 37.9 |
| median | 42.5 | 38.0 | 49.0 | 38 |
| F (%) | 48 (60%) | 37 (69%) | 49 (61%) | 48 (53%) |
| Time between vaccines (days) | | | | |
| range | NA | 14-61 | 68-76 | - |
| mean | 21 | 29.1 | 70.1 | - |
| median | 21 | 26 | 70 | - |
| Blood sampling after second vaccine (days) | | | | |
| range | 27-32 | 15-75 | 23-35 | - |
| mean | 27.9 | 32.0 | 29.0 | - |
| median | 28 | 30 | 29 | - |

150

Serum levels of anti-SARS-CoV-2 S

CoronaVac-CoronaVac

CoronaVac-AZD1222

AZD1222-AZD1222

Convalescent patients

